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Abstract
 Globally, stroke is the second leading cause of death. DespiteIntroduction:
the burden of illness and death, few acute interventions are available to
patients with ischemic stroke. Over 1,000 potential neuroprotective
therapeutics have been evaluated in preclinical models. It is important to use
robust evidence synthesis methods to appropriately assess which therapies
should be translated to the clinical setting for evaluation in human studies. This
protocol details planned methods to conduct a systematic review to identify and
appraise eligible studies and to use a network meta-analysis to synthesize
available evidence to answer the following questions: in preclinical in vivo
models of focal ischemic stroke, what are the relative benefits of competing
therapies tested in combination with the gold standard treatment alteplase in (i)
reducing cerebral infarction size, and (ii) improving neurobehavioural
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 Any reports and responses or comments on
the article can be found at the end of the
article.
reducing cerebral infarction size, and (ii) improving neurobehavioural
outcomes?
 We will search Ovid Medline and Embase for articles on the effectsMethods:
of combination therapies with alteplase. Controlled comparison studies of
preclinical  models of experimentally induced focal ischemia testing thein vivo 
efficacy of therapies with alteplase versus alteplase alone will be identified.
Outcomes to be extracted include infarct size (primary outcome) and
neurobehavioural measures. Risk of bias and construct validity will be
assessed using tools appropriate for preclinical studies. Here we describe
steps undertaken to perform preclinical network meta-analysis to synthesise all
evidence for each outcome and obtain a comprehensive ranking of all
treatments. This will be a novel use of this evidence synthesis approach in
stroke medicine to assess pre-clinical therapeutics. Combining all evidence to
simultaneously compare mutliple therapuetics tested preclinically may provide
a rationale for the clinical translation of therapeutics for patients with ischemic
stroke. 
: Review findings will be submitted to a peer-reviewed journalDissemination
and presented at relevant scientific meetings to promote knowledge transfer.
 PROSPERO number to be submitted following peer review.Registration:
Keywords
stroke, preclinical, systematic review, network metaanalysis, network
meta-analysis,
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Introduction
Globally, an estimated 15 million people suffer a stroke; stroke is 
the second leading cause of death, with six million people dying 
and an additional five million becoming permanently disabled 
each year1,2. The costs of stroke are high due to a combination 
of immediate high costs from acute care and long-term costs 
from resulting disability. Worldwide cost estimates range from 
$266 billion to $1.038 trillion per year3. Despite the enormous 
human and economic burden, only four acute interventions 
are currently used clinically: patient care in a dedicated 
stroke unit3, reperfusion (by pharmacological thrombolysis 
or endovascular mechanical thrombectomy4), oral aspirin, and 
surgical decompression.
In the search for novel therapies for acute stroke, more than 
1,000 potential neuroprotective therapeutics (e.g. anticoagu-
lants, calcium channel blockers, free radical scavengers, GABA 
mimetics, etc.) have been evaluated in preclinical models5. Of 
these, only reperfusion with tissue plasminogen activators6, such 
as alteplase3, has had a preclinical basis. Despite its efficacy, 
alteplase has inherent limitations such as the risk of hemorrhagic 
transformation, which warrants exploration of novel adjunctive 
therapies that can maximize therapeutic benefit. Combina-
tion therapies with alteplase might limit reperfusion injury and 
cell death that can sometimes occur with this drug. However, 
given the multitude of therapies tested preclinically (and 
multiple mechanisms of action) it is difficult to assess which 
therapies should proceed to clinical testing.
Preclinical systematic reviews have served as a robust form 
of knowledge synthesis to evaluate transparently experimen-
tal therapies for more than a decade7–9. Previous preclinical 
systematic reviews have compared treatments in isolation using 
pair-wise meta-analyses, which limits the ability to simulta-
neously evaluate comparative effectiveness in the presence 
of many treatments of interest. Use of network meta-analysis 
(NMA) in comparative effectiveness research to study the rela-
tive benefits and harms of multiple interventions in humans9,10 
has risen dramatically during the past decade11. Such analy-
ses allow the comparison of many interventions based on all 
‘direct’ and ‘indirect’ information. In addition, this approach 
has the potential to establish a more rigorous framework for 
decisions to embark on clinical trials while reducing risks to 
human trial participants and the enormous costs of preclinical 
translation3,7,12. Comparison of preclinical stroke therapeutics 
represents an excellent case study for such work. Given the 
novelty of this approach, this systematic review will also serve 
as a case study to empirically explore the methodological 
nuances of applying NMA in a preclinical setting.
Protocol
This protocol will be registered in the international prospective 
register of systematic reviews (PROSPERO, CRD) following 
peer review. Our review protocol is reported in accordance with 
the Preferred Reporting Items in Systematic reviews and Meta-
Analysis-Protocol guidelines (a complete checklist is available 
as Supplementary File 1)13. Post-protocol adjustments will be 
included in the final report.
Objectives
Primary objective. We will perform a systematic review and 
NMAs to address the following question: amongst in vivo 
models of focal ischemic stroke, what are the relative benefits 
of competing therapies tested in combination with the gold 
standard treatment alteplase14 in (i) reducing cerebral infarction 
size, and (ii) improving neurobehavioural outcomes?
Secondary Objective. We will also (i) assess the risk of bias of 
the included studies, and (ii) explore what novel considerations 
for statistical adjustments are necessary for NMA of preclinical 
studies (e.g. method of ischemic induction, timing of treat-
ment, species, sex, and comorbidities). We will also evaluate the 
challenges of applying NMA to preclinical studies (e.g. 
consistency, heterogeneity, availability of key study covariates).
Methods
Search and study identification
An information specialist (RS) will construct a search strategy 
based on a previous review of comparative stroke therapies, 
and limit them to include studies which compared therapies 
to alteplase (representative search strategy is provided in 
Supplementary File 2)15. Search strategies will be peer reviewed 
by a second information specialist using the peer review of elec-
tronic search strategy method16. Searches of Ovid MEDLINE 
and Embase will be carried out for articles on the effects of 
combination therapies with alteplase (Supplementary File 2 
contains the search strategy). Of note, no language or date 
restrictions will be used. We will also search the CAMA-
RADES database which contains data extracted from existing 
preclinical systematic reviews on stroke15,17–28. In addition to 
this rigorous search, we will assess bibliographies of any new 
studies and reviews identified. Articles in foreign languages will 
be translated.
Study eligibility criteria
Eligibility criteria to identify relevant studies for the current review 
were established in considering the Population-Intervention- 
Comparators-Outcomes-Study design (PICOS) framework29.
Population. Preclinical in vivo models of experimentally induced 
focal ischemia will be sought. All species/strains of animals 
will be eligible. Both female and male animals will be included. 
Neonatal animals will be excluded; however, all other ages 
will be considered. Studies in which focal ischemic stroke was 
established by transient occlusion of the middle cerebral artery 
or anterior cerebral artery via any method (chemical, embolic, 
mechanical, thermal) will be eligible. Animal models of 
haemorrhagic stroke, global or hemispheric brain ischemia, 
models of permanent occlusion without reperfusion (e.g. photo-
thrombosis, cauterization), or delayed reperfusion such that it is 
considered permanent will be excluded30. Human studies and 
tissue culture studies will be excluded.
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Intervention and comparator. Studies where the treatment 
in combination with alteplase (e.g. alteplase + hypothermia) 
is compared with alteplase alone in animals that have experi-
mentally induced focal ischemia will be eligible. Studies that 
compare more than one active treatment such as alteplase + 
hypothermia versus alteplase +FK506 (i.e. head to head compar-
isons) will also be included. Studies must include alteplase as a 
‘foundational’ therapeutic in experimental arms to be eligible. All 
delivery routes and doses will be considered. To increase poten-
tial clinical relevance (i.e. construct validity), only studies that 
deliver therapies within 6 hours of induction of focal ischemic 
stroke will be included.
Outcome measures
-    Primary outcome. Infarct size is a measure of injury 
reduction at the infarct site in the brain and can be meas-
ured via a variety of quantifiable techniques through non-
invasive techniques (e.g. T2-weighted magnetic resonance 
imaging) or post-mortem analysis (e.g. staining of brain 
sections using hematoxylin and eosin). This is the most 
widely reported outcome in preclinical stroke studies. 
Infarct size outcomes will be extracted at the latest time 
point for each study. Separate time-point specific analyses 
will be conducted (e.g. an early time point <30 days vs 
later time points >30 days).
-     Secondary outcome. Neurobehavioural measures repre-
sent a valuable means of assessing functional recovery 
after treatment. Neurobehavioural assessment are sen-
sitive to detecting the array of impairments, including 
motor/sensory deficits (e.g. ladder rung walking—foot 
slip errors) as well as memory/learning deficits (e.g. 
Morris water maze)31,32. These outcomes, while labour-
intensive, are typically reported with less frequency than 
infarct volume even though functional outcomes may 
have the greatest clinical relevance)33,34. Neurobehavioral 
outcomes will be extracted at all timepoints and sepa-
rate time-point specific analyses will be conducted as 
described above.
Study design
Controlled comparison studies testing the efficacy of therapies 
+ alteplase versus alteplase alone will be sought.
Screening and study selection
Two reviewers (A.D. and H.S.C.), will review abstracts (Stage 1 
screen) and full text reports (Stage 2 screen) from search results 
independently and in duplicate against the eligibility criteria 
below using Distiller SR® software (Evidence Partners, 
Ottawa, ON) to identify relevant articles. Discrepancies will 
be resolved through discussion with a senior team member 
(M.L. and D.C.). Both stages of screening will begin with 
a calibration exercise to ensure consistent application of 
eligibility criteria. A PRISMA flow diagram35 will be presented 
to document the process of study selection.
Data extraction
Two independent reviewers (A.D. and H.S.C.) will review 
studies and extract data into standardized, piloted forms 
implemented in Microsoft Excel (Microsoft Corporation, Seattle, 
Washington, USA). Discrepancies will be resolved through 
discussion with a senior team member. We will collect data 
related to, but not limited to, animal characteristics (Table 1); 
stroke model (Table 1); intervention (Table 2a, b); and out-
comes (Table 3), as well as study ID (authors, year), and study 
design characteristics. Measures of central tendency (e.g. mean) 
and dispersion (e.g. standard deviation) will be extracted as 
reported. Data in graphical format will be extracted using 
Engauge Digitizer36. When measures of central tendency and 
dispersion or sample sizes are missing (or cannot be measured 
digitally), authors will be contacted; if authors do not respond, the 
data will be excluded.
Assessment of risk of bias and construct validity
Two independent reviewers will assess the risk of bias of each 
included study (quality of the design, conduct and analysis for 
the experiment)37. We will assess the risk of bias using a modi-
fied version of the Cochrane Risk of Bias Tool for randomized 
trials (Table 4). Risk of bias will be summarized38 with descrip-
tive statistics and presented graphically using standard methods 
and radar charts. The assessment of risk of bias will play 
an important role in exploring potential limitations of the 
evidence base and establishing the feasibility of incorporating 
relevant adjustments in NMA models. The construct valid-
ity of included studies (i.e. degree to which experimental model 
and design reflect the clinical entity of stroke and its treatment) 
will be assessed using elements from the CAMARADES 
checklist alongside criteria established by expert consensus 
(Table 5).
Exploring the evidence and synthesizing outcome data 
using network meta-analysis
We will begin by exploring the pattern of treatment compari-
sons represented by the included set of studies using network 
diagrams (or using a tabular approach if necessary, should the 
number and pattern of comparisons be too broad to be summa-
rized graphically). Effect estimates from all included studies 
will be summarized. We will summarize traits of included 
studies focusing on clinical (e.g. age, sex, species, stroke model, 
reperfusion vs. permanent model, comorbidities, severity of 
infarct pre-treatment, infarct location)39 and methodological 
(e.g. risk of bias, timing of outcome assessment) features27, and 
review these with our clinical and preclinical experts to estab-
lish the degree of homogeneity within the included studies. 
For NMA, given the possibility that a large proportion of the 
studied interventions may have been evaluated in only a single 
study (and many could potentially yield very large effect sizes, 
which may not have been substantiated by more animals in 
more studies), we will exclude these interventions from NMAs 
performed; each of these treatments removed from NMA will 
neither benefit from “borrowing strength” through NMA, nor 
end up with a summary estimate and confidence interval dif-
ferent from what was reported in a single study. The reported 
findings for the outcomes of interest from studies removed 
from the NMA according to these criteria will be summarized 
separately in descriptive tables to ensure all relevant data are 
summarized. This approach will also restrict the network to a more 
practical size and reduce the risk of computational challenges.
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Table 1. Study characteristics.
Question Responses
Exclude Study Yes (provide reason for exclusion) or No
RefID Text
First Author Text
Year of Publication Text
Correspondence (Author, Email) Text
Funding Support Not Reported 
Government 
Industry 
Academic Institution 
Charity 
Foundation 
Other 
Unclear
Country of Corresponding Author Canada 
China 
Japan 
South Korea 
United States 
Other 
Unclear
Species Mouse 
Rat 
Rabbit 
Swine 
Mini-Swine 
Sheep 
Dog 
Monkey 
Other
Strain Text
Sex Male, Female, Both or Unclear
If Both Proportion of Male and Female Stated (Text)
Weight Text or Not Reported
Age Text or Not Reported
Type of Model Intraluminal Suture 
MCA Embolism 
Photothrombosis 
Endothelin 1 Vasoconstriction 
Tamura 
MCA Clip 
Small Vessel Stroke 
Other 
Not Reported
Duration of Follow Up from Initiation of Disease State Text with Units or Unclear
Where there is homogeneity of important effect modifiers, we 
will perform NMAs to compare interventions9,10,40, following 
procedures to assess the validity of the assumptions of homoge-
neity, similarity, and consistency41. Based upon the extracted 
study characteristics, we will work with our clinical and pre-
clinical experts to establish any additional novel aspects of 
preclinical studies that may be important to consider in relation 
to judgements regarding study homogeneity beyond those antici-
pated in preparing this protocol. We have anticipated different 
species of animals (rats, mice, gerbils, dogs, sheep, non-human 
primates) across studies. We also anticipate that multiple 
reporting formats will have been used to assess both infarct 
volume (e.g. mm3, % of hemisphere or total brain, etc.) and 
neurobehavioral changes (e.g. seconds, % of baseline). 
For meta-analysis of preclinical studies, the normalized mean 
difference (NMD) scale is useful in serving the purpose of 
synthesizing the complexity of data aforementioned42. Prior to 
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Table 2. Study interventions with alteplase.
a. Combination therapy with alteplase
Questions Responses
N Initially Reported? Text
Time to Alteplase Administration Post-
Stroke (h)?
Time Provided (Text) 
Unclear
Frequency of Alteplase Administration? Single Dose 
Multiple Dose (Text) 
Unclear
Dose of Alteplase Delivered Text
Category of the Comparative Therapy Nonpharmacological 
Pharmacological 
Reperfusion 
Surgical 
Cell Based Therapy 
Other
Comparative Therapy Type Abciximab, Albumin, Alpha-PBN, Annexin, Anti-CD18, Aortic Occlusion, Argatroban, 
Atorovastatin, Citicoline, Clopidogrel, CP101,606-27, Dizocilpine, Edaravone, Eliprodil, 
Enlimonab, EPO, Estrogen, GCSF, Heparin, Hypothermia, Insulin, MC-1, Melagatran, 
Melatonin, Minocycline, NBQX, Normobaric Oxygen, Pentasaccharide, Pravastatin, 
PS519, Rosiglitazone, Rosuvastatin, S-0139, Tacrolimus, Tirilizad, TS-011, UK-279, 276, 
Velcade, XG-102, YM872, Other (Text)
Was the comparative therapy delivered 
before, with, or after alteplase?
Prior to Administering Alteplase 
In Conjunction with Alteplase 
After Delivering Alteplase 
Unclear
Time to Comparator Administration 
Post-Stroke (h)?
Time Provided (Text) 
Unclear
Frequency of Comparative Therapy 
Administration
Single 
Multiple (Text) 
Other (Text) 
Unclear (Text)
Dose of Comparative Therapy Delivered Text
Mode of Comparative Therapy Delivery Intravenous 
Intra-Arterial 
Oral 
Other (Text) 
Not Reported
b. Alteplase monotherapy
Question Response
N Reported Text
Monotherapy Type Abciximab, Albumin, Alpha-PBN, Annexin, Anti-CD18, Aortic Occlusion, Argatroban, 
Atorovastatin, Citicoline, Clopidogrel, CP101,606-27, Dizocilpine, Edaravone, Eliprodil, 
Enlimonab, EPO, Estrogen, GCSF, Heparin, Hypothermia, Insulin, MC-1, Melagatran, 
Melatonin, Minocycline, NBQX, Normobaric Oxygen, Pentasaccharide, Pravastatin, 
PS519, Rosiglitazone, Rosuvastatin, S-0139, Tacrolimus, Tirilizad, TS-011, UK-279, 276, 
Velcade, XG-102, YM872, alteplase
Time to Monotherapy Administration 
Post-Stroke?
Time Provided (Text) or Unclear
Dose of Monotherapy Delivered Text
Frequency of Administration of 
Monotherapy
Single, Multiple (Text), Other, Unclear
Mode of Monotherapy Delivery Intravenous, Intraarterial, Oral, Other (Text), Unclear
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Table 3. Outcomes.
Question Responses
If outcome was measured, indicate the latest time point measured in days.
Infarct Volume (Primary Outcome of Interest) Yes, No 
If yes, indicate latest time point
Neurobehavioral Outcomes Measured (Secondary Outcome of Interest)
Walking Test Yes, No 
If yes, indicate latest time point
Forelimb Asymmetry Tests Yes, No 
If yes, indicate latest time point
Skilled Reaching Tests Yes, No 
If yes, indicate latest time point
Adhesive Removal Test Yes, No 
If yes, indicate latest time point
Measures of General Neurological Status: Neurological Severity Scores (mNSS) Yes, No 
If yes, indicate latest time point
Measures of General Neurological Status: Rotarod Yes, No 
If yes, indicate latest time point
Other Relevant Neurobehavioral Test Yes (Text), No 
If yes, indicate test used and time point
Table 4. Risk of bias.
Question Responses
Sequence Generation Low risk = Randomization was mentioned and good method used 
High risk = Randomized but poor method used 
High risk = Non-randomized 
Unclear risk = Randomized but no method described 
Unclear risk = No mention of randomized or non-randomized
Allocation Concealment Low risk = Method used to conceal the allocation sequence is described in sufficient detail 
Unclear risk = Insufficient information to determine if the allocation sequence was concealed 
High risk = The allocation sequence was not concealed or was concealed in a poor manner
Blinding of Personnel Low risk = All personnel involved in giving intervention were blinded to the study groups 
Unclear = Insufficient information to determine if any personnel giving intervention were blinded to 
the study groups 
High risk = All personnel giving intervention were described to be unblinded to the study groups
Blinding of Outcome Assessment Low risk (all) = Outcome assessors were blinded to the study groups for each outcome assessed 
Low risk (some) = Outcome assessors were blinded to the study groups for at least one outcome 
assessed. Select the outcomes that were blinded 
Unclear = Insufficient information to determine if outcome assessors were blinded during assessment 
High risk = Outcome assessors not blinded to the study groups
Incomplete Outcome Data Low risk = N values were consistent between methods and results for all outcomes, or inconsistent  
N values were explained (e.g. only N=3 animals were selected for histological analysis) 
Unclear = The N value was either not presented in the methods or in the results, and therefore there 
is insufficient information to permit judgment 
High risk = N values were not consistent between methods and results for the final outcomes without 
explanation of attrition or were inconsistent between outcomes
Potential Bias due to the Source 
of Funding
Low risk = Non-industry source of funding (or no funding) 
High risk = Any industry source of funding 
Unclear = Funding source not reported
Potential Bias due to the Sample 
Size Calculation
Low risk = Sample size calculations were correctly performed and followed 
High risk = Sample size calculations were incorrectly performed or followed 
Unclear = Sample size calculations were not reported
Potential Bias due to Reported 
Conflict of Interest
Low risk = Authors reported no conflict of interest 
High risk = Authors reported potential conflict of interest 
Unclear = Potential conflicts of interest not reported
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performing NMAs, we will perform traditional pairwise meta-
analyses on the NMD scale for each comparison in the treatment 
networks where two or more studies are available to explore 
heterogeneity based on the I2 statistic29. To perform network 
meta-analyses on the NMD scale, we will use an established 
model from the National Institute in Health and Care Excel-
lence’s TSD series43, adapting its identity link to the log link 
in order to conduct the NMA on a log ratio of means (logRoM) 
scale. The log ratio of means of the kth treatment and the “stroke 
only” control, dk = logRoMC,Tk, can be estimated after model fitting, and the corresponding NMD estimate is:
                   1 – exp{logRoMC,Tk} = 1 – exp (dk)
The NMD of the kth treatment in comparison with alteplase 
(k=1) is 1 – exp (dk – d1).
Both fixed- and random-effect Bayesian NMAs will be per-
formed using a common heterogeneity parameter according 
to established methods10,40,43. Model fit will be assessed by 
comparing the model’s posterior total residual deviance with the 
number of unconstrained data points43. Selection between mod-
els will be based on deviance information criteria (DIC), with a 
difference of five points suggesting an important difference43. 
All pairwise comparisons between interventions will be 
expressed with both summary point estimates and correspond-
ing 95% credible intervals. Vague prior distributions will be 
assigned for all measures of treatment effect, as well as for the 
between-study variance parameter in random effects analyses. 
NMAs will be performed using OpenBUGS software version 
3.2.344 and the R Package R2OpenBUGS45. Model convergence 
will be assessed using established methods including assessment 
Table 5. Construct validity.
Question Responses
Was an adult animal used? 
Rats: ≥ 6 weeks 
Mice: ≥ 8 weeks 
Rabbit: ≥ 6 months 
Sheep: ≥ 38 weeks 
Dog: ≥ 6 months 
Cats: ≥ 6 months 
Minipig: ≥6 months 
Swine: ≥ 6 months 
Monkey (Macaques): ≥ 4 years
Yes: Age was explicitly reported 
Yes: Study only mentions “adult” 
No: Age was explicitly stated but is under the 
standard “adult age” 
Unclear: Age was not reported 
Unclear: Age and weight unreported (but not 
labelled as a neonate)
Animals Present with Comorbidities Commonly Associated with 
Ischemic Stroke?
Yes (Text) 
No 
Unclear
Avoidance of Anesthetics with Neuroprotective Effects (i.e. Ketamine) Yes (Text) 
No (Text) 
Unsure 
Not Reported
Physiological Monitoring During Stroke 
If yes, indicate which parameters were monitored
Yes (Text) 
No 
Unsure 
Not Reported
Was the ischemic stroke injury confirmed via laser Doppler or perfusion 
imaging?
Yes 
No 
Not Reported 
Unclear
Was there use of a battery of sensory-motor recovery tests? 
These tests include: 
1. Walking Tasks (e.g. Beam, Grid Walking or Ladder Tests) 
2. Forelimb Asymmetry Tests (e.g. cylinder tests) 
3. Skilled Reaching Tests (e.g. Staircase or Single Pellet Reaching Task) 
4. Adhesive Removal Test 
5. Neurological Severity Scores (mNSS) 
6. Rotarod
Yes: Multiple tests were used 
No: Only one test was used 
No: No sensory motor recovery tests were used 
Unclear
Was the size of infarct proportional to that seen in a human stroke 
patient?
Yes: Infarct size within reasonable limits (<40%) 
No: Infarct size was too large (>40%) 
Unclear: Infarct size was not reported 
Other (Text)
Did the duration of occlusion create a clinically relevant infarct size? Yes: Duration of stroke was <90 min 
No: Duration of stroke was >/= 90 min 
No: Stroke model was permanent 
Unclear (Text)
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of Rhat (the potential scale reduction factor) and the Gelman- 
Rubin convergence diagnostic to see if they are near 19. 
Surface under the cumulative ranking (SUCRA) values, and 
the mean rank of each intervention (with 2.5% and 97.5% quan-
tiles) will also be estimated for each intervention46. Forest plots 
of treatment comparisons versus “stroke with no treatment” 
control as well as versus stroke + alteplase will be prepared 
for each outcome. Given the anticipated high number of inter-
ventions assessed in only a single study, a tabular approach 
to summarizing findings will be employed for them. We will 
also undertake forest plots of effects wherein interventions are 
ordered according to mean rank estimated from NMA.
Addressing heterogeneity and inconsistency
To check the validity of the consistency assumption (i.e., tran-
sitivity of the effect size through common comparators), a 
consistency model as well as an unrelated mean effects 
model will be fit to the data47. We will compare their respec-
tive DIC values to check model fitting and their posterior mean 
deviance contribution per study to check the consistency 
assumption. We will also assess the magnitude of the estimated 
between-study SD measure from both models, as a reduction in 
this parameter in the inconsistency model also provides evidence 
of inconsistency.
The likelihood of important clinical and methodological het-
erogeneity between studies is anticipated by the research team 
to be high and may include several nuances which are unique 
to the pre-clinical setting. First, several vital aspects of pre-
clinical studies from our risk of bias assessments (described 
earlier) may be important adjustment factors that could have 
an important impact on the findings from NMAs, including 
randomization and blinding24,48. In this work, we will use sub-
group analyses or covariate-adjusted analyses to address and 
explore the impact that covariates have on findings and to estab-
lish the robustness of findings from primary syntheses49,50. We 
will assess the possibility to adjust for the following group level 
factors: animal species (e.g. mouse) and strain (e.g. C57Bl6 
strain of mice), model of stroke, average animal age, percent-
age of female subjects, average time since stroke induction, 
combination therapies, cerebral blood flow, temperature, infarct 
location and severity, use of randomization and blinding of 
experimenters and outcome assessments. Alternatively, when 
combining data from different species, we could model animal 
species as an extra level in the hierarchical model for treatment 
effect, allowing for heterogeneity across species and assum-
ing that treatment effects are similar across species around an 
overall mean effect. For the network structure, primary analyses 
will be performed at the treatment level. As dose may 
have an important effect on intervention benefits, we will also 
explore the range of doses associated with each intervention 
across studies to consider additional analyses. However, as dose 
response characteristics of different agents may also vary between 
animal species and an a priori source of information to estab-
lish appropriate dose categories is not available, any analyses 
pursued in relation to dose will be appropriately indicated as 
post-hoc. Findings from all analyses will be reported. Given 
the anticipated complexity of this novel application of NMA, 
we anticipate separate publications will be required for the 
primary and secondary outcomes.
Dissemination
The results of the study will be submitted for publication to a 
peer-reviewed journal and presented at relevant national and 
international conferences and scientific meetings to promote 
knowledge transfer.
Amendments
If amendments are required for this protocol, date of each amend-
ment will be provided with a description for rationale for the 
change in this section.
Discussion
Current approaches to evaluating the relative therapeutic ben-
efit of preclinical treatments for stroke are limited. Although 
systematic reviews have been conducted comparing more than a 
thousand candidates, many have never been systematically 
assessed, nor have they been assessed relative to one another, 
or more importantly, to the best available clinical treatment 
(alteplase). Use of NMA to synthesize data on all relevant avail-
able therapies may help address this knowledge gap. Thinking 
more broadly, the proposed review, with the application and 
evaluation of NMA to preclinical therapeutics, will inform 
translational scientists’ knowledge of which preclinical stroke 
therapeutics have the most promise for either further preclinical 
research or translation to clinical trial.
In addition to addressing an important question for clinical 
research, we anticipate this study will inform empirical explora-
tions of anticipated challenges of evidence synthesis that are 
unique to the pre-clinical setting. First, a debate among pre-
clinical and clinical scientists is likely to exist regarding both 
the appropriateness and approach to synthesizing outcome data 
from different species as well as different models of stroke. Sec-
ond, there exists an especially important need to consider a 
broad range of adjustments to account for between-study 
heterogeneity related to animal characteristics or other features; 
lack of availability of these key data may be sub-optimal. Our 
study will provide an empirical evaluation of the degree of 
missingness of features, such as those significant to experimen-
tal design (e.g. randomization). This will provide an indication 
of the changes to the available evidence when exploring 
adjustments of comparisons. More specifically, if the lack of 
reporting proves to be severe, this will provide further high-
level evidence that educational efforts are needed to improve 
the completeness of reporting of preclinical research51.
Other challenges potentially requiring consideration will include 
identifying optimal strategies for presenting findings (including 
those with many comparators rendering analysis unfeasible), 
analysis of studies with small sample sizes, and strategies 
to select the most promising therapy to translate clinically. 
We anticipate that this systematic review will provide insight 
into these and other methodologic challenges and thereby 
serve as an exemplar for future NMA of preclinical data to build 
upon.
Page 9 of 14
F1000Research 2019, 8:11 Last updated: 19 MAR 2019
Findings from this review will be shared with several key 
knowledge users including (i) the Stroke Treatment Academic 
Industry Roundtable52 for development of future guidelines; 
(ii) the Heart & Stroke Foundation and the Canadian Partnership 
for Stroke Recovery to inform future potential trials51; (iii) the 
Cochrane Stroke Group to inform a future clinical system-
atic review and NMA; and (iv) stroke survivors, via sharing of 
findings with our knowledge users.
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confounders/effect modifiers in the primary analysis itself. This is already mentioned on page 12 for
the 'covariate-adjusted analyses'. 
Please provide a list upfront of the potential factors you want to correct for (in order of
importance/usage) and provide an explanation on the number of factors you want to correct for
(potentially based on the number of included studies?). To my knowledge this is different form the
stated 'review these with our clinical and preclinical experts to establish the degree of
homogeneity' and would add to your future primary analysis. This also means that the studies does
not necessarily need to be homogenous for your primary analysis, as the metaregression will
appoint a certain effect to these 'covariables' (and will correct for the covariable). 
Please provide a minimum number of comparisons for a certain intervention/comparison to be
included in the network meta-analysis. Will there also be 2 or more, as with the traditional pairwise
meta-analysis mentioned? If no minimum can be mentioned upfront, please explain why. 
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Yes
Page 13 of 14
F1000Research 2019, 8:11 Last updated: 19 MAR 2019
 Yes
Are sufficient details of the methods provided to allow replication by others?
Yes
Are the datasets clearly presented in a useable and accessible format?
Not applicable
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